Drugmakers crowd the next wave of obesity drugs as GLP-1 market widens beyond early leaders
Pharma companies are accelerating obesity drug programs to challenge Novo Nordisk and Eli Lilly, aiming at oral options, combo regimens, and broader indications as investors assess market share shifts and supply-demand dynamics.